Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
ipo
5
×
life sciences
national blog main
national top stories
san francisco blog main
san francisco top stories
5
×
boston top stories
cancer
clinical trials
deals
new york blog main
new york top stories
san diego blog main
san diego top stories
san francisco
sanofi
startups
third rock ventures
venture capital
warp drive bio
biogen
boulder/denver blog main
boulder/denver top stories
cancer drugs
deerfield management
detroit blog main
detroit top stories
europe blog main
europe top stories
fda
gilead sciences
indiana blog main
indiana top stories
melinta therapeutics
national
novartis
raleigh-durham blog main
raleigh-durham top stories
What
medicines
5
×
ipo
bio
cancer
covid
deal
new
proteins
research
revolution
roundup
acquisitions
activity
aiming
ambys
announced
approvals
big
biogen
biotech
cancer’s
ceo
clamped
collabs
control
daniel
deadly
debuted
delays
despite
developing
disease
diseases
drug
economic
family
fast
fda
formed
frontiers
Language
unset
Current search:
medicines
×
ipo
×
" san francisco top stories "
×
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?